NRx Pharmaceuticals Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
RADNOR, Pa., May 6, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ( " NRx Pharmaceuticals " , the " Company " ), a clinical stage pharmaceutical company, today announced a statistically significant safety advantage of NRX-101 compared to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 6, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Study to Evaluate the Efficacy of VR for Bipolar Disorder
Conditions: Bipolar Disorder; VR; Interventional Study Interventions: Device: VR therapy; Device: VR sham Sponsors: Shanghai Mental Health Center; Nanjing XR-Oasis Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 3, 2024 Category: Research Source Type: clinical trials
Hemostatic Forceps vs. Bipolar Electrocautery Probes for High-Risk Bleeding Gastroduodenal Ulcers
Conditions: Gastroduodenal Ulcer Interventions: Device: Hemostatic Forceps; Device: Bipolar Electrocautery Probes Sponsors: Mahidol University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2024 Category: Research Source Type: clinical trials
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
RADNOR, Pa., April 30, 2024, NRx Pharmaceuticals, Inc. ( " NRx Pharmaceuticals " , the " Company " ), a clinical stage pharmaceutical company today that its Breakthrough Therapy designated investigational drug NRX-101 vs lurasidone demonstrated a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 1, 2024 Category: Pharmaceuticals Source Type: clinical trials
Lifestyle MIND- Feasibility for Randomized Wait-list Control Trial
Conditions: Type 2 Diabetes Mellitus; Serious Mental Illness; Schizophrenia; Major Depression; Bipolar Disorder Interventions: Behavioral: Lifestyle MIND Sponsors: The University of Texas Health Science Center at San Antonio Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Honest Open Proud for Psychotic and Bipolar Disorder in Norway
Conditions: Psychotic Disorders; Bipolar Disorder; Disclosure Interventions: Behavioral: Honest Open Proud program Sponsors: Oslo University Hospital; University of Oslo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders —a double-blind, randomized, placebo-controlled proof-of-concept study
This study will provide a first proof-of-concept on the potential of the TSPO ligand etifoxine in the treatment of depressive disorders.Trial registrationClinical Trials Register (EudraCT number:2021-006773-38, registration date: 14 September 2022) and German Register of Clinical Studies (DRKS number:DRKS00031099, registration date: 23 January 2023). (Source: Trials)
Source: Trials - April 22, 2024 Category: Research Source Type: clinical trials
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Conditions: Major Depressive Episode Associated With Bipolar I or Bipolar II Disorder Interventions: Drug: Lumateperone; Drug: Placebo Sponsors: Intra-Cellular Therapies, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder
Conditions: Bipolar Disorder; Bipolar Disorder Type 1 Interventions: Dietary Supplement: Glucose; Dietary Supplement: Ketones Sponsors: Stony Brook University; Massachusetts General Hospital; Mclean Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Prospective evaluation of blood biomarkers as an aid to diagnostic and treatment in drug-naive patients with depression
Conditions: Depressive Disorder; Bipolar Disorder; Bipolar Depression Sponsors: Les Toises - Psychiatry and Psychotherapy Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
Conditions: Mental Disorder; Schizophrenia; Major Depressive Disorder; Bipolar I Disorder Interventions: Drug: Placebo IEM tablet; Drug: Abilify MyCite ®; Device: D-Tect Patch Sponsors: Otsuka Pharmaceutical Development& Commercialization, Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Effect of Intermittent and Continuous Theta Burst Stimulation on Sleep, Daytime Sleepiness, and Fatigue in Depression
Conditions: Unipolar Depression; Bipolar Disorder Interventions: Device: iTBS; Device: cTBS; Device: Sham Sponsors: Jakub Antczak; Institute of Psychiatry and Neurology, Warsaw Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Evaluation of blood biomarker-based diagnostic aid in outpatients suffering from depression
Conditions: Depressive Disorder; Bipolar Disorder; Bipolar Depression Interventions: Other: there is no intervention Sponsors: Les Toises - Psychiatry and Psychotherapy Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Theta-Burst Stimulation for Bipolar Depression
Conditions: Bipolar Depression; Bipolar Disorder; Treatment- Resistant Bipolar Disorder; Type 2 Bipolar Disorder Interventions: Device: iTBS Stimulation; Device: Sham iTBS Stimulation Sponsors: Centre for Addiction and Mental Health; University Health Network, Toronto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Ningbo Severe Mental Disorders Cohort
Conditions: Severe Mental Disorder; Schizophrenia; Bipolar Disorder; Schizo-Affective Psychosis; Paranoid Psychoses; Mental Retardation; Epileptic Psychosis Interventions: Other: Patient with severe mental disorder without intervention Sponsors: Ningbo University; The Affiliated Kangning Hospital of Ningbo University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
